A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity
Each medication, in turn, requires a specific delivery device technology.12 Reflecting on the success of already-marketed devices, it is evident that future cardiometabolic treatments will rely in large part on proven drug delivery technologies, like two-step single-use autoinjectors
The drug's manufacturer, Novo Nordisk, declined to comment
Shoemaker AH, Silver HJ, Buchowski M, Slaughter JC, Yanovski JA, Elfers C, et al
Studies have shown that people achieve and maintain an average weight loss of 60% of excess body weight in the first year following the gastric sleeve or mini gastric bypass procedure
You can buy a great electrolyte, a great protein, and a great fiber separately, but unless someone designed them to share doses, sugar levels, formats, and a daily rhythm built for GLP-1 reality, you've got three soloists, not an ensemble